Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV-focus on pegylated interferon-alpha

International Journal of Nanomedicine

Volumn 1, Issue 4, 2006, Pages 399-409

  Zoller, Heinz ^a   Vogel, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Hepatitis C; HIV; Pegylated interferon alpha; Ribavirin

Indexed keywords

ALPHA INTERFERON; DRUG CARRIER; MACROGOL DERIVATIVE;

CHEMISTRY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; NANOMEDICINE; REVIEW; TREATMENT OUTCOME;

DRUG CARRIERS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; NANOMEDICINE; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 34548642712     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/nano.2006.1.4.399     Document Type: Review

References (75)

1. Abonyi ME, Lakatos PL. 2005.Ribavirin in the treatment of hepatitis C. Anticancer Res, 25:1315-20.
2. Akuta N, Suzuki F, Suzuki Y, et al. 2005. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol, 40:688-96.
3. Alter MJ. 2006. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44:S6-9.
4. Belle SH, Beringer KC, Detre KM. 1996. Recent findings concerning liver transplantation in the United States. In Terasaki PI, Cecka JM (eds). Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory. p 15-30.
5. Bergamini A, Bolacchi F, Cepparulo M, et al. 2001. Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Clin Exp Immunol, 123:459-64.
6. Bica I, McGovern B, Dhar R, et al. 2001. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis, 32:492-7.
7. Caliceti P. 2004. Pharmacokinetics of pegylated interferons: what is misleading? Dig Liver Dis, 36(Suppl 3):S334-9.
8. Carlsson T, Reichard O, Norkrans G, et al. 2005. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat, 12:473-80.
9. Carrat F, Bani-Sadr F, Pol S, et al. 2004. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA, 292:2839-48.
10. Chatelut E, Rostaing L, Gregoire N, et al. 1999. A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol, 47:365-71.
11. Chen SL, Morgan TR. 2006. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci, 3:47-52.
12. Chung RT, Andersen J, Volberding P, et al. 2004. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med, 351:451-9.
13. Chung RT, He W, Saquib A, et al. 2001. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc Natl Acad Sci U S A, 98:9847-52.
14. Dahari H, Major M, Zhang X, et al. 2005. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology, 128:1056-66.
15. Darby SC, Ewart DW, Giangrande PL, et al. 1997. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet, 350:1425-31.
16. De Clercq E. 2004. Antiviral drugs in current clinical use. J Clin Virol, 30:115-33.
17. de Ledinghen V, Trimoulet P, Winnock M, et al. 2002. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. J Hepatol, 36:819-26.
18. Dianzani F. 1993. Biological basis for the clinical use of interferon. Gut, 34:S74-6.
19. Fattovich G, Giustina G, Degos F, et al. 1997. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology, 112:463-72.
20. Ferenci P. 2003. More effective by design. Hoffmann-La Roche Ltd.
21. Ferenci P. 2004. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis, 24 (Suppl 2):25-31.
22. Ferenci P, Fried MW, Shiffman ML, et al. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol, 43:425-33.
23. Gish RG. 2006.Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother, 57:8-13.
24. Grace MJ, Lee S, Bradshaw S, et al. 2005. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem, 280:6327-36.
25. Glue P. 1999. The clinical pharmacology of ribavirin. Semin Liver Dis, 19:17-24.
26. Glue P, Fang JW, Rouzier-Panis R, et al. 2000. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther, 68:556-67.
27. Graci JD, Cameron CE. 2006. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol, 16:37-48.
28. Gupta SK, Pittenger AL, Swan SK, et al. 2002. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol, 42:1109-15.
29. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med, 140:346-55.
30. Harris JM, Martin NE, Modi M. 2001. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet, 40:539-51.
31. Heathcote J, Main J. 2005. Treatment of hepatitis C. J Viral Hepat, 12:223-35.
32. Hellen CU, Pestova TV. 1999. Translation of hepatitis C virus RNA. J Viral Hepat, 6:79-87.
33. Herrmann E, Zeuzem S. 2006. The kinetics of hepatitis C virus. Eur J Gastroenterol Hepatol, 18:339-42.
34. Hoofnagle JH. 2002. Course and outcome of hepatitis C. Hepatology, 36:S21-9.
35. Ideo G, Bellobuono A. 2002. New therapies for the treatment of chronic hepatitis C. Curr Pharm Des, 8:959-66.
36. Jessner W, Stauber R, Hackl F, et al. 2003. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat, 10:37-42.
37. Jessner W, Watkins-Riedel T, Formann E, et al. 2002. Hepatitis C viral dynamics: basic concept and clinical significance. J Clin Virol, 25 Suppl 3:S31-9.
38. Kamal SM, Fehr J, Roesler B, et al. 2002. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology, 123:1070-83.
39. Kato T, Date T, Miyamoto M, et al. 2005. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol, 43:5679-84.
40. Kenny-Walsh E. 1999. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med, 340:1228-33.
41. Laguno M, Murillas J, Blanco JL, et al. 2004. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. Aids, 18:F27-36.
42. Lebray P, Nalpas B, Vallet-Pichard A, et al. 2005. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antivir Ther, 10:769-76.
43. Lee WM, Reddy KR, Tong MJ, et al. 1998. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group. Hepatology, 28:1411-5.
44. Lehmann M, Meyer MF, Monazahian M, et al. 2004. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol, 73:387-91.
45. Leone N, Rizzetto M. 2005. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol, 51:31-46.
46. Lesens O, Deschenes M, Steben M, et al. 1999. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis, 179:1254-8.
47. Liu XD, Xie L, Han KQ, Liu GQ. 1996. Weibull function fits to pharmacokinetic data of ribavirin in man. Eur J Drug Metab Pharmacokinet, 21:227-31.
48. Manns MP, McHutchison JG, Gordon SC, et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-65.
49. Manns MP, Wedemeyer H. 2004. Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step. JAMA, 292:2909-13.
50. Margot NA, Miller MD. 2005. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antivir Ther, 10:343-8.
51. Morse GD, Shelton MJ, O'Donnell AM. 1993. Comparative pharmaco-kinetics of antiviral nucleoside analogues. Clin Pharmacokinet, 24:101-23.
52. Murashima S, Kumashiro R, Ide T, et al. 2000. Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients. J Med Virol, 62:185-90.
53. Musselman DL, Lawson DH, Gumnick JF, et al. 2001. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med, 344:961-6.
54. Neumayr G, Propst A, Schwaighofer H, et al. 1999. Lack of evidence for the heterosexual transmission of hepatitis C. QJM, 92:505-8.
55. Nunez M, Camino N, Ramos B, et al. 2005. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther, 10:657-62.
56. Patel K, McHutchison J. 2001. Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. Expert Opin Pharmacother, 2:1307-15.
57. Pawlotsky JM. 2006. Therapy of hepatitis C: from empiricism to eradication. Hepatology, 43:S207-20.
58. Pedder SC. 2003. Pegylation of interferon alfa: structural and pharmaco-kinetic properties. Semin Liver Dis, 23(Suppl 1):19-22.
59. Perelson AS, Neumann AU, Markowitz M, et al. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 271:1582-6.
60. Petrenkiene V, Gudinaviciene I, Jonaitis L, et al. 2004. Improvement of liver histopathology in patients with hepatitis C after interferon and ribavirin combination therapy. Medicina (Kaunas), 40:962-8.
61. Racial/ethnic disparities in diagnoses of HIV/AIDS-33 states, 2001-2004. 2006. MMWR Morb Mortal Wkly Rep, 55:121-5.
62. Rockstroh JK, Mocroft A, Soriano V, et al. 2005. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis, 192:992-1002.
63. Rodriguez-Torres M, Torriani FJ, Soriano V, et al. 2005. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother, 49:3997-4008.
64. Salmon-Ceron D, Lassalle R, Pruvost A, et al. 2003. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial. Clin Infect Dis, 36:1295-304.
65. Schaefer M, Schmidt F, Folwaczny C, et al. 2003. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology, 37:443-51.
66. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology, 36:S35-46.
67. Sherman KE, Rouster SD, Chung RT, et al. 2002. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis, 34:831-7.
68. Sulkowski MS, Thomas DL. 2003. Hepatitis C in the HIV-Infected Person. Ann Intern Med, 138:197-207.
69. Tam RC, Lim C, Bard J, Pai B. 1999. Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by type 1 cytokine polarization, regulation of IL-10 expression, and costimulatory signaling. J Immunol, 163:3709-17.
70. Thomas HC, Torok ME, Forton DM, et al. 1999. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol, 31(Suppl 1):152-9.
71. Terrault NA. 2002. Sexual activity as a risk factor for hepatitis C. Hepatology, 36:S99-105.
72. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. 2004. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med, 351:438-50.
73. Tsubota A, Arase Y, Someya T, et al. 2005. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol, 75:27-34.
74. Veronese FM, Pasut G. 2005. PEGylation, successful approach to drug delivery. Drug Discov Today, 10:1451-8.
75. Zeuzem S, Welsch C, Herrmann E. 2003. Pharmacokinetics of peginter-ferons. Semin Liver Dis, 23(Suppl 1):23-8.